Association Between 18F‑FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases
10.1007/s13139-024-00843-8
- Author:
Jonathan R. YOUNG
1
;
Julie A. RESSLER
;
Joanne E. MORTIMER
;
Daniel SCHMOLZE
;
Mariko FITZGIBBONS
;
Bihong T. CHEN
Author Information
1. Department of Radiology, Division of Neuroradiology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte 91010, CA, USA
- Publication Type:ORIGINAL ARTICLE
- From:Nuclear Medicine and Molecular Imaging
2024;58(3):113-119
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The objective of this study was to evaluate whether uptake on 18F-fluorodeoxyglucose ( 18F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases.
Methods:In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast cancer brain metastases, we analyzed both preoperative 18F-FDG PET/CT and HER2 status of the resected/biopsied brain specimens. The maximum standardized uptake values (SUVmax) of the lesions were normalized to contralateral normal white matter and compared using Mann–Whitney U tests.
Results:The study cohort was comprised of 12 women with breast cancer with a mean age of 59 years (range: 43–76 years) with a total of 14 distinct brain metastatic lesions. The SUVmax ratio of HER2-positive breast cancer brain metastases was significantly greater than that of HER2-negative lesions (3.98 vs 1.79, U = 38.00, p = 0.008).
Conclusion:The SUVmax ratio may help to identify the HER2 status of breast cancer brain metastases, if validated prospectively.
